Newsletter Xagena

Dementia: HMG-CoA reductase inhibitors do not reduce risk

A study, led by University of Washington in Seattle, found the use of HMG-CoA reductase inhibitors, also known as statins, was not associated with a reduced risk of Alzheimer's disease or other types of dementia.

HMG-CoA reductase inhibitors may reduce cardiovascular risk by inhibiting cholesterol synthesis or through anti-inflammatory effects, biological mechanisms which may play a role in the development of dementia, particularly Alzheimer's disease.

Previous studies have suggested that HMG-CoA reductase inhibitors may have a protective effect on the process of dementia, preventing or delaying onset.

Thomas D. Rea, of the University of Washington, Seattle, and colleagues assessed data on 2,798 participants 65 years or older in the Cardiovascular Health Study who underwent baseline magnetic resonance imaging ( MRI ) and took a standardized mental test to determine that they were free of dementia when enrolled in the study ( between 1991 and 1994 ).

At baseline, information on their health status, cognitive function and medication use, as well as laboratory assessments and diagnostic testing was collected.
Participants were followed up annually to assess their health status, medication use and whether they had developed dementia.
During a total of 15,030 person years ( number of individuals followed over time until development of disease or end of the study ) of follow-up, there were 480 cases of dementia, including 245 attributable to Alzheimer's disease alone.

After controlling for other known or suspected risk factors, the researchers found that patients who had ever used statins had no reduction in their risk of developing dementia from any cause ( Alzheimer's disease, mixed Alzheimer's disease and vascular dementia or vascular dementia alone ) compared with those who had never used statins.

"Several factors may explain why statin use was not associated with a lower risk of dementia," the authors write. "Participants were on average 75 years of age, and statin use was assessed for a median of five years. Statin exposure may need to occur earlier in adulthood or for longer periods to prevent dementia, although analyses that stratified the duration of statin use did not suggest a duration-dependent association."

"In this investigation, statin therapy was not associated with a lower risk of dementia," the authors concluded. "Although statin use is an important treatment for cardiovascular disease, additional investigation is needed to determine whether and for whom statin use may affect dementia risk."